Highlights from the recent Becton Dickinson (BDx) coverage includes a focus on the Dividend King's performance. Despite facing challenges, the company is still regaled as a value investment. Major financial institutions such as Stifel and Barclays retain their bullish stance on the global medical technology company, reiterating buy and overweight ratings, respectively. Conversely, some observers raised concerns about Becton Dickinson underperforming the healthcare sector and its stock downgraded. The company has recently paid an $85M settlement to investors.
Moreover, BDx intends to separate its Biosciences and Diagnostic Solutions business and is considering the potential divestment of the life sciences unit at a $30 billion valuation. The company is also currently unveiling advanced cell analyzers with innovative spectral and imaging features. Meanwhile, the company's earnings are keenly anticipated, with an intent to announce its Q1 2025 figures as well as their Q3 2025 fiscal outcomes. The financial results of Q1 and Q3, as well as 53rd consecutive year of dividend increase, underpin Becton Dickinson's contributions to the industry.
Becton Dickinson and BDX News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Mon, 09 Jun 2025 15:44:00 GMT - Rating 0 - Innovation 6 - Information 7 - Rumor -4
